About this item:

182 Views | 121 Downloads

Author Notes:

G. Baker Hubbard, III, MD, Associate Professor of Ophthalmology 1365B Clifton Rd. NE Atlanta, GA 30322, Phone: 404-778-5224, Fax: 404-778-4380, ghubba2@emory.edu.

Design and conduct of the study (VYH, SY, GBH); Collection (VYH, SY, GBH, CSB, JY, BEC, TWO); Management (SY, GBH, TWO, CSB, JY, BEC); Analysis (VYH, SY, GBH, TWO); Interpretation of the data (VYH, GBH, SY, TWO); Preparation, review, or approval of the manuscript (VYH, GBH, SY, TWO, CSB, JY, BEC)

GBH receives a consulting fee from the Children’s Hospital of Philadelphia Research Institute as a consultant/expert reader for the Telemedicine Approaches to Evaluating Acute-phase Retinopathy of Prematurity Study (eROP Study); He also has financial activity outside the submitted work involving expert witness testimony.

There were no other financial disclosures from the remaining authors.


Research Funding:

Supported in part by an Unrestricted Grant from Research to Prevent Blindness Inc. (New York, NY); and NIH Core Grant EYO 6360 (Bethesda, MD)


  • Science & Technology
  • Life Sciences & Biomedicine
  • Ophthalmology

Short-Term Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Treated With Other Vascular Endothelial Growth Factor Inhibitors


Journal Title:

American Journal of Ophthalmology


Volume 156, Number 1


, Pages 23-28

Type of Work:

Article | Post-print: After Peer Review


Purpose: To report results of aflibercept therapy in eyes with neovascular age-related macular degeneration previously treated with bevacizumab, ranibizumab, or both. Design: Retrospective, interventional, noncomparative, consecutive case series. Methods: Ninety-six eyes from 85 patients with neovascular age-related macular degeneration who previously had received bevacizumab, ranibizumab, or both were treated with aflibercept monthly for 3 months followed by a fourth injection within 2 months. Outcomes were determined 4 ± 1 months after the first aflibercept dose and included: proportion of patients gaining or losing 2 lines or more of best-corrected visual acuity, proportion remaining within a gain or loss of 1 line, mean change in logarithm of the minimal angle of resolution visual acuity, mean change in central foveal thickness, mean change in macular cube volume, and qualitative anatomic response as assessed by spectral-domain optical coherence tomography. Results: At baseline, 82 (85%) eyes had signs of active exudation despite a mean of 17 previous anti-vascular endothelial growth factor injections. At final visit, 82 (85%) remained stable within a gain or loss of 1 line, 7 (7%) gained 2 lines or more, and 7 (7%) lost 2 lines or more of best-corrected visual acuity. Mean logarithm of the minimal angle of resolution visual acuity showed minimal change 0.02 (range, -0.46 to 0.70; P =.14). Mean central foveal thickness decreased -18 μm (range, -242 to 198 μm; P =.06). Mean macular volume decreased -0.27 mm3 (95% confidence interval, -0.4 to -0.1 mm3; P =.004). On qualitative analysis, 4 (5%) eyes had complete resolution of exudative fluid, 40 (49%) showed partial resolution, 26 (32%) remained unchanged, and 12 (14%) showed worsened exudative fluid. Conclusions: Aflibercept seems to be an effective alternative for neovascular age-related macular degeneration patients previously treated with bevacizumab, ranibizumab, or both at 4 months of follow-up. Most treated eyes demonstrated stable visual acuity and anatomic improvements by spectral-domain optical coherence tomography.

Copyright information:

© 2013 by Elsevier Inc. All rights reserved.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote